Clinical Trial Update: Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney Allograft [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial is evaluating whether a single dose of rituximab (375 mg/m2) can prevent Epstein-Barr virus infection and post-transplant lymphoprolife…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epstein-barr Virus Infections
• Post-transplant Lymphoproliferative Disorder

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: University Hospital, Strasbourg, France | Conditions: Epstein-Barr Virus Infections | Phase 4 | Status: RECRUITING